Teva Pharmaceutical Industries Ltd. (TEVA)

Teva Pharmaceutical is the world’s largest manufacturer of generic drugs by volume. The company makes hundreds of pharmaceutical products — pills, injectables, and other formulations — that treat conditions ranging from diabetes and heart disease to infections and neurological disorders. Almost every major hospital, pharmacy, and healthcare system in the world stocks Teva drugs. The company operates factories on multiple continents, manages supply chains for raw ingredients, and sells to customers in more than 150 countries. Teva’s business is to make medicine available, affordable, and available reliably at scale. It does this by manufacturing drugs that lost their patents decades ago, so competitors are free to make them as well. Teva competes on cost, scale, and reliability rather than innovation.

From Israeli pharmaceutical house to global generics giant

Teva was founded in 1901 in Jerusalem as a small pharmacy compounding medicines by hand. It remained a regional business for decades, serving the Israeli market. In the 1980s, as the company expanded beyond Israel, it discovered an opportunity: countries around the world were beginning to permit and incentivise the use of generic pharmaceuticals — drugs chemically identical to brand-name drugs whose patents had expired. Brand-name drug manufacturers charge high prices because they have exclusive legal rights to sell the drug. Once a patent expires, any manufacturer can make and sell that same drug, competing on price. Generic drugs are far cheaper, often 80 or 90 percent less expensive than the brand-name original.

Teva recognized that this market — generic drugs — was huge and growing. It was an industry in which innovation in the drug itself did not matter. What mattered was manufacturing capability, supply chain reliability, and the ability to move drugs to market at low cost. Teva began acquiring generic-drug companies in the United States, Europe, and elsewhere. It invested in manufacturing facilities. It built regulatory expertise to navigate the approval process in different countries. By the early 2000s, Teva had become the world’s largest manufacturer of generic drugs by volume.

How the generics business works

When a pharmaceutical company invents a new drug, it patents the chemical formula, giving it exclusive rights to make and sell the drug for a set number of years — typically 20 years from the patent filing date. During that period, the patent holder can charge whatever the market will bear. Once the patent expires, any other pharmaceutical company can manufacture and sell the same drug. Generic-drug makers file applications with regulators, demonstrating that their version is chemically equivalent and manufactured to the same quality standards as the brand-name original. Once approved, the generic can be sold, typically under a different name and at a fraction of the original price.

Teva’s business depends on a steady stream of brand-name drugs losing their patents. A major cancer drug, heart medication, or antibiotic goes generic, and suddenly Teva can start making it. If Teva is among the first to launch a generic version, it can gain significant market share and margins. As more competitors enter, prices fall toward the cost of manufacture, and margins compress. The economics of a given generic product might be excellent for a year or two, then thin out over time as it becomes commodity.

To keep growing, Teva must continuously launch new generics as old drugs lose patent protection. It must also gain and hold market share against other generic manufacturers. Success requires scale in manufacturing, an extensive sales force to reach hospitals and pharmacies, regulatory expertise to navigate approvals in different countries, and the ability to produce drugs at the lowest possible cost. Teva has invested heavily in all four.

The ingredient problem

A critical but underappreciated part of Teva’s business is the manufacture of active pharmaceutical ingredients, or APIs — the chemical substances that make a drug work. Many generic manufacturers buy their APIs from suppliers in China and India, where labour and manufacturing costs are low. Teva manufactures many of its own APIs, giving it better control over costs, quality, and supply reliability. This vertical integration is an advantage during supply disruptions but also means Teva faces the raw-material and labour-cost pressures that affect chemical manufacturing everywhere. When petrochemical prices spike or shipping costs surge, it affects Teva’s costs directly.

Geographic reach and regulatory complexity

Teva’s revenue is spread across the United States, Europe, and the rest of the world. The United States is the largest market for generic drugs by value, even though generic penetration is high — most prescriptions in the United States are now filled with generics rather than brand-name drugs. Europe is another major market but with different regulatory frameworks. Prices are regulated in many European countries, which limits Teva’s ability to raise prices. Emerging markets in Latin America, Eastern Europe, and Asia offer growth opportunities but often require manufacturing plants in-country and navigation of local regulations and political risks.

Each country’s regulatory environment is different. The United States Food and Drug Administration approves generics through a specific pathway that assumes equivalence to a brand-name reference drug. European authorities have a separate approval route. Other countries have their own rules. Teva has to maintain regulatory expertise across dozens of jurisdictions and ensure its manufacturing plants meet the standards of each market it serves. This complexity is partly a moat — a smaller competitor might struggle to maintain compliance in so many places — but it is also an operational burden that increases costs.

Margin pressure and pricing power

The generic-drug industry is inherently competitive. Teva’s pricing power is limited. In many cases, a drug is manufactured by dozens of competitors, pushing prices toward the cost of production. Healthcare systems and insurers, aware that many generic options exist for any given drug, negotiate aggressively and shop around. Teva cannot easily raise prices without losing market share to cheaper competitors. Margin compression is the industry norm.

In recent years, Teva has faced additional pressures. The rise of biosimilars — generic-like versions of expensive biologic drugs — represents a new competitive frontier. Teva is investing in biosimilar manufacturing but so are its rivals. Additionally, healthcare consolidation (large hospital systems and pharmacy benefit managers combining) has increased buyer power, making it harder for any single generic manufacturer to negotiate good pricing.

Strategic challenges: speciality and innovation

Recognising that the core generic business faces structural margin pressure, Teva has been trying to diversify into speciality generic drugs — drugs that require special handling, administration, or patient support, and that command higher margins even in generic form. These include complex injectables, respiratory drugs, and treatments requiring monitoring. Teva has also acquired rights to branded drugs that remain on-patent, giving it exposure to innovation-driven businesses with higher margins. The challenge is that acquiring branded drugs requires upfront cash and brings R&D risk, a very different game from generics manufacturing.

Debt and financial stress

Teva has historically carried substantial debt to finance acquisitions and manufacturing expansion. High debt levels leave little room for error if market conditions deteriorate. A downturn in healthcare spending, a major generic drug facing an unexpected price war, or disruption in the supply chain could strain Teva’s ability to service its debt and invest in new capacity. The company’s financial flexibility depends on maintaining reasonable profitability and cash generation, which in turn depends on sustaining volume and managing costs tightly.

How to research Teva

Understanding Teva requires looking at its annual 10-K filing (SEC CIK 0000818686), which breaks revenue by geographic region and by speciality versus generic. The filing discusses competitive dynamics, pricing pressures, and supply-chain risks. Quarterly earnings calls reveal trends in demand, pricing, and costs. Key metrics include the number of generic drugs Teva manufactures, the number of first-to-market launches it achieves each quarter, gross margins by segment, and the trends in key pricing markets like the United States. Because Teva’s business is driven by volume and cost management rather than innovation, the best signals of health are operational metrics — manufacturing efficiency, market-share gains or losses, and the pace of new generic launches.